ATTLAS Quality of Life: Four-Drug Regimen Shows No Detectable Global Decline
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Kang EJ, Park S, Kim TM, et al.
Nov 17, 2026 · Published in: Cancer Medicine
Assessing QoL in lung cancer: Atezolizumab plus bevacizumab shines despite chemo challenges.
Anti-CD38 Quadruplets Lead MRD Rankings; Transplant Benefit Remains Unproven
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Caridà G, Scalise L, Mosca A, et al.
Nov 14, 2026 · Published in: Cancers
Anti-CD38 regimens excel in achieving MRD negativity in myeloma.
Pertuzumab Dual Blockade Holds Up; Denosumab, Atezolizumab, Bevacizumab Add Little in HER2+ Disease
Analysis Oncology Pharmacy Confirmatory Grade: Moderate
Alfaro-Muñoz L, Avedillo-Salas A, Vicente-Romero J, et al.
Nov 14, 2026 · Published in: Cancers
Pertuzumab shows promise in treating aggressive HER2-positive breast cancer.
Dirozalkib Halves Progression Risk Versus Crizotinib in First-Line ALK-Positive NSCLC
Analysis Oncology Pharmacy Confirmatory Grade: Moderate
Liu Y, Meng X, Yu Y, et al.
Nov 11, 2026 · Published in: Cancer Communications (London, England)
Dirozalkib shows superior efficacy to crizotinib in ALK-positive NSCLC.
Primary Endocrine Therapy vs Surgery in Older ER-Positive Breast Cancer: Biology Defines Candidates
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Carleton N, Zou J, Mu Y, et al.
Nov 6, 2026 · Published in: JAMA Network Open
No survival difference found between endocrine therapy and surgery in older breast cancer patients.
ICI Rechallenge After irAEs: One in Five Face Grade 3 or Higher Toxicity
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Chen X, Gao S, Zhang X, et al.
Nov 6, 2026 · Published in: Cancer Medicine
Rechallenging ICIs after adverse events shows high toxicity but promising disease control.
Chemoimmunotherapy in Early TNBC: Higher pCR, Fragile Survival Signal, Added Toxicity
★ Editor's Pick Analysis Oncology Pharmacy Confirmatory Grade: Low
Wu J, Zhang K
Nov 6, 2026 · Published in: Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer
ICIs and chemotherapy boost outcomes in early-stage TNBC.
Perioperative Tislelizumab Preserves Quality of Life and Eases Chest Pain, Cough in NSCLC
Analysis Oncology Pharmacy Confirmatory Grade: Moderate
Yue D, Cappuzzo F, Wang W, et al.
Nov 6, 2026 · Published in: Future Oncology (London, England)
Tislelizumab improves lung cancer patients' quality of life by reducing symptoms.
Perioperative Pembrolizumab in Resectable HNSCC: Ten-Year Evidence Review
Analysis Oncology Pharmacy Confirmatory Grade: Moderate
Freeman H, Rawson C, Al-Saidi N, et al.
Nov 6, 2026 · Published in: Exploration of Targeted Anti-tumor Therapy
Pembrolizumab shows promise in perioperative treatment of resectable HNSCC.
Pooled PD-1/PD-L1 Cervical Cancer Meta-Analysis Shows OS Benefit, With Overlap Concerns
★ Editor's Pick Analysis Oncology Pharmacy Confirmatory Grade: Moderate
Luo R, Li M, Ma L, et al.
Nov 3, 2026 · Published in: Frontiers in Immunology
PD-1 inhibitors extend survival in metastatic cervical cancer.
Fewer Versus More Neoadjuvant Chemoimmunotherapy Cycles in Resectable Esophageal Squamous Cell Carcinoma
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Lv H, Wang Z, Su C, et al.
Nov 1, 2026 · Published in: World Journal of Surgical Oncology
Neoadjuvant cycles in esophageal cancer: flexibility or necessity?
Two Versus Three Induction Cycles in Nasopharyngeal Carcinoma: Equal Survival, More Toxicity
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Xie R, Lin X, Li Q, et al.
Oct 30, 2026 · Published in: BMC Cancer
Two chemo cycles reduce toxicity in nasopharyngeal cancer.
Nivolumab Plus Chemotherapy in Gastric Cancer Patients Aged 75 and Older: Real-World Feasibility
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Yoshimatsu M, Morita S, Ueta Y, et al.
Oct 30, 2026 · Published in: World Journal of Surgical Oncology
Also in Geriatrics
Can older gastric cancer patients benefit from nivolumab plus chemotherapy?
One-Hour Antibiotic Rule Not Supported in Post-HSCT Neutropenic Fever
Analysis Infectious Disease / Antimicrobials Hypothesis-generating Grade: Low
Windham SL, Guidry CA, Sung AD, et al.
Oct 28, 2026 · Published in: Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Also in Oncology
Does the one-hour rule for antibiotics matter in stem cell transplants?
Second-Line HCC After TKI Failure: Efficacy Versus Toxicity Network Analysis
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Li X, Nie G, Wang Y, et al.
Oct 24, 2026 · Published in: Frontiers in Immunology
Also in Gastroenterology / Hepatology
Pembrolizumab outshines others in post-TKI hepatocellular carcinoma treatment.